Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

TherapeuticsMD to resubmit NDA for rebuffed vaginal pain candidate TX-004HR

November 10, 2017 8:44 PM UTC

After a Nov. 3 meeting with FDA, TherapeuticsMD Inc. (NYSE-M:TXMD) said the agency will not require the company to conduct an additional safety study before resubmitting an NDA for TX-004HR to treat moderate to severe vaginal pain during sexual intercourse associated with vulvar vaginal atrophy due to menopause. TherapeuticsMD said it plans to submit the NDA within the coming weeks.

In May, TherapeuticsMD said FDA issued a complete response letter for TX-004HR that cited a lack of long-term endometrial safety data beyond the 12-week Phase III Rejoice trial. In September, the company submitted to FDA a review of medical literature on the use of vaginal estrogen products, including information on the risk of endometrial hyperplasia or cancer (see BioCentury, May 11)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Therapeuticsmd Inc.